Experience

1910 Genetics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Scientific Officer

  • Oct 2023 - Present

  Boston, Massachusetts, United States

• Senior Vice President and Head of Chemistry

  • May 2023 - Sep 2023

  Boston, Massachusetts, United States



Nocion Therapeutics, Inc.

• United States
• Biotechnology
• 1 - 100 Employee

• Senior Vice President

  • Jan 2020 - Apr 2023

  Waltham, Massachusetts, United States

• Vice President

  • Aug 2018 - Dec 2019

  Cambridge, MA Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company’s platform of unique molecular entities selectively affects inflamed nociceptors. Treatment using this approach aims to provide more durable and robust local analgesic effects while minimizing numbness or paralysis and other systemic off-target effects. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory… Show more Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company’s platform of unique molecular entities selectively affects inflamed nociceptors. Treatment using this approach aims to provide more durable and robust local analgesic effects while minimizing numbness or paralysis and other systemic off-target effects. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons. For more information, visit: www.nociontx.com.



Axial Therapeutics, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Vice President

  • Jul 2017 - Aug 2018

  Greater Boston Area



Flatley Discovery Lab

• United States
• Biotechnology
• 1 - 100 Employee

• Vice President

  • Feb 2011 - Jun 2017

  Charlestown, MA Flatley Discovery Lab is an independent not-for-profit research organization focused on discovering small molecules that restore ΔF508-CFRT protein function to treat Cystic Fibrosis. As the head of Chemistry I built up the chemistry resources at FDL while leading the main research program from HTS through development of preclinical candidate FDL169, which is on track to initiate first-in-man clinical studies 4Q 2014. As a key member of the leadership team my responsibilities include medicinal… Show more Flatley Discovery Lab is an independent not-for-profit research organization focused on discovering small molecules that restore ΔF508-CFRT protein function to treat Cystic Fibrosis. As the head of Chemistry I built up the chemistry resources at FDL while leading the main research program from HTS through development of preclinical candidate FDL169, which is on track to initiate first-in-man clinical studies 4Q 2014. As a key member of the leadership team my responsibilities include medicinal chemistry, CMC, CTM, DMPK and toxicokinetics. Show less



Surface Logix

• Biotechnology Research
• 1 - 100 Employee

• Vice President, Discovery Research

  • Nov 2008 - Feb 2011

  As the head of Discovery my staff and I conducted novel research and supported development of three clinical candidates. I closely directed medicinal chemistry in addition to managing bio-analytical analysis of plasma/tissue samples, in vivo pharmacology, ADME research and some in vitro biology. Using WinNonlin modeling software I performed pharmacokinetic and toxicokinetic analyses to support in vivo discovery, preclinical toxicology and human clinical studies.

• Vice President, Chemistry

  • May 2006 - Oct 2008

  As Vice President of Chemistry I directed medicinal chemistry research to identify novel back-up molecules to three clinical assets in addition to initiating new research programs that have yielded novel lead molecules with desired in vivo pharmacology to establish proof of concept for those programs. Working closely with my team we enhanced surface chemistries for our SAM-based technology platform and have presented our results externally at regional and national ACS meetings.



ASDI

• SAB

  • 2009 - 2010

  Consultant for drug discovery services.



PFIZER LABORATORIES PFE

• South Africa
• Biotechnology Research
• 1 - 100 Employee

• Associate Director

  • Sep 2004 - Apr 2006

  As an Associate Director I managed a diverse group of scientists responsible for hit to lead medicinal chemistry, high throughput purification of SAR compounds, chemistry technology projects and QC of screening plates and liquid compound files

• Senior Principal Scientist, Chemistry

  • Aug 2001 - Sep 2004

  As a Senior Principal Scientist I was a founding member of the Cambridge Chemistry group. My team and I discovered a series of novel 11bHSD-1 inhibitors for the treatment of type-2 diabetes.

• Project Leader

  • Dec 2000 - Aug 2001

  As Project Leader I led a group of medicinal chemists working on the development of novel GPCR ligands for the treatment of metabolic disorders.

• Senior Research Scientist

  • Jan 2000 - Nov 2000

  As Senior Research Scientist I conducted research that identified novel Melanocortin receptor-IV ligands.



Pfizer

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Research Scientist

  • Jun 1997 - Jan 2000

  As a Research Scientist I developed enterocyte-selective MTP inhibitors for the treatment of obesity and made significant SAR contributions to the discovery of the marketed drug Slentrol.